| 1. |
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
|
| 2. |
Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg, 1993, 165(1): 68-72.
|
| 3. |
Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg, 1997, 21(2): 195-200.
|
| 4. |
NCCN. The NCCN Pancreatic Adenocarcinoma Clinical Practice Guidelines in oncology, 2018 version 1. https://www.nccn.org/professionals/physician_gls/default.aspx.
|
| 5. |
NCCN. The NCCN Pancreatic Adenocarcinoma Clinical Practice Guidelines in oncology, 2016 version 1. https://www.nccn.org/professionals/physician_gls/default.aspx.
|
| 6. |
Tang K, Lu W, Qin W, et al. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Pancreatology, 2016, 16(1): 28-37.
|
| 7. |
Ishikawa O, Ohigashi H, Imaoka S, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple’s procedure for adenocarcinoma of the pancreatic head? Arch Surg, 1994, 129(10): 1075-1080.
|
| 8. |
Roland CL, Yang AD, Katz MH, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol, 2015, 22(4): 1168-1175.
|
| 9. |
Youngwirth LM, Nussbaum DP, Thomas S, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18 243 patients. J Surg Oncol, 2017, 116(2): 127-132.
|
| 10. |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19): 1817-1825.
|
| 11. |
Rombouts SJ, Walma MS, Vogel JA, et al. Systematic Review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol, 2016, 23(13): 4352-4360.
|
| 12. |
Chllamma MK, Cook N, Dhani NC, et al. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer, 2016, 115(6): 649-654.
|
| 13. |
Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol, 2015, 22(4): 1153-1159.
|
| 14. |
Hoffman JP, Lipsitz S, Pisansky T, et al. Phase Ⅱ trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol, 1998, 16(1): 317-323.
|
| 15. |
Ychou M, Conroy T, Seitz JF, et al. An open phase Ⅰ study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol, 2003, 14(3): 481-489.
|
| 16. |
Nanda RH, El-Rayes B, Maithel SK, et al. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol, 2015, 111(8): 1028-1034.
|
| 17. |
Liu GF, Li GJ, Zhao H. Efficacy and toxicity of different chemotherapy regimens in the treatment of advanced or metastatic pancreatic cancer: a network meta-analysis. J Cell Biochem, 2018, 119(1): 511-523.
|
| 18. |
Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol, 2016, 17(6): 801-810.
|
| 19. |
Lee JC, Kim JW, Ahn S, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity. Eur J Cancer, 2017, 76: 125-133.
|
| 20. |
Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas, 2013, 42(8): 1311-1315.
|
| 21. |
Petrelli F, Coinu A, Borgonovo K, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas, 2015, 44(4): 515-521.
|
| 22. |
Li X, Ma T, Zhang Q, et al. Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population. Cancer Lett, 2017, 406: 22-26.
|
| 23. |
Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postoperative complications. Ann Surg Oncol, 2018, 25(3): 626-637.
|
| 24. |
Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications. Am J Clin Oncol, 2016, 39(3): 302-313.
|
| 25. |
Kim YE, Park MS, Hong HS, et al. Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer. Radiology, 2009, 250(3): 758-765.
|
| 26. |
Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol, 2017, 27(7): 3104-3116.
|
| 27. |
Speicher MR, Pantel K. Tumor signatures in the blood. Nat Biotechnol, 2014, 32(5): 441-443.
|
| 28. |
Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun, 2015, 6: 7686.
|
1/5
WeChat